TY - JOUR
T1 - Secondary cancers after a childhood cancer diagnosis
T2 - a nationwide hospital-based retrospective cohort study in Japan
AU - Ishida, Yasushi
AU - Qiu, Dongmei
AU - Maeda, Miho
AU - Fujimoto, Junichiro
AU - Kigasawa, Hisato
AU - Kobayashi, Ryoji
AU - Sato, Maho
AU - Okamura, Jun
AU - Yoshinaga, Shinji
AU - Rikiishi, Takeshi
AU - Shichino, Hiroyuki
AU - Kiyotani, Chikako
AU - Kudo, Kazuko
AU - Asami, Keiko
AU - Hori, Hiroki
AU - Kawaguchi, Hiroshi
AU - Inada, Hiroko
AU - Adachi, Souichi
AU - Manabe, Atsushi
AU - Kuroda, Tatsuo
N1 - Publisher Copyright:
© 2015, Japan Society of Clinical Oncology.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Background: The epidemiology of secondary cancers in childhood cancer survivors has been unknown in Asian countries. Our aim is to assess the incidence and risk factors for secondary cancers through a nationwide survey in Japan. Methods: A retrospective cohort study comprising 10,069 children who were diagnosed with cancer between 1980 and 2009 was conducted in 15 Japanese hospitals. The cumulative incidence rate was calculated using death as the competing risk and compared by the Gray method. The standardized incidence ratio (SIR) was defined as the ratio of the number of observed cancers divided by the number of expected cancers. The risk factors were analyzed using Cox regression analysis. Results: One hundred and twenty-eight patients (1.3 %) developed secondary cancers within a median follow-up of 8.4 years. The cumulative incidence rate was 1.1 % (95 % confidence interval [CI] 0.9–1.4) at 10 years and 2.6 % (95 % CI 2.1–3.3) at 20 years after primary cancer diagnosis. Sensitivity analysis, limited to 5-year survivors (n = 5,387), confirmed these low incidence rates. The SIR of secondary cancers was 12.1 (95 % CI 10.1–14.4). In the Cox analysis, the hazard ratios for secondary cancers were 3.81 (95 % CI 1.53–9.47) for retinoblastoma, 2.78 (95 % CI 1.44–5.38) for bone/soft tissue sarcomas, and 1.81 (95 % CI 1.16–2.83) for allogeneic stem cell transplantation. Conclusions: The cumulative incidence of secondary cancers in children in Japan was not high; however, the SIR was relatively high. Retinoblastoma or sarcoma in addition to allogeneic stem cell transplantation were significant risk factors for secondary cancers.
AB - Background: The epidemiology of secondary cancers in childhood cancer survivors has been unknown in Asian countries. Our aim is to assess the incidence and risk factors for secondary cancers through a nationwide survey in Japan. Methods: A retrospective cohort study comprising 10,069 children who were diagnosed with cancer between 1980 and 2009 was conducted in 15 Japanese hospitals. The cumulative incidence rate was calculated using death as the competing risk and compared by the Gray method. The standardized incidence ratio (SIR) was defined as the ratio of the number of observed cancers divided by the number of expected cancers. The risk factors were analyzed using Cox regression analysis. Results: One hundred and twenty-eight patients (1.3 %) developed secondary cancers within a median follow-up of 8.4 years. The cumulative incidence rate was 1.1 % (95 % confidence interval [CI] 0.9–1.4) at 10 years and 2.6 % (95 % CI 2.1–3.3) at 20 years after primary cancer diagnosis. Sensitivity analysis, limited to 5-year survivors (n = 5,387), confirmed these low incidence rates. The SIR of secondary cancers was 12.1 (95 % CI 10.1–14.4). In the Cox analysis, the hazard ratios for secondary cancers were 3.81 (95 % CI 1.53–9.47) for retinoblastoma, 2.78 (95 % CI 1.44–5.38) for bone/soft tissue sarcomas, and 1.81 (95 % CI 1.16–2.83) for allogeneic stem cell transplantation. Conclusions: The cumulative incidence of secondary cancers in children in Japan was not high; however, the SIR was relatively high. Retinoblastoma or sarcoma in addition to allogeneic stem cell transplantation were significant risk factors for secondary cancers.
UR - http://www.scopus.com/inward/record.url?scp=84948971250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948971250&partnerID=8YFLogxK
U2 - 10.1007/s10147-015-0927-z
DO - 10.1007/s10147-015-0927-z
M3 - Article
C2 - 26620038
AN - SCOPUS:84948971250
SN - 1341-9625
VL - 21
SP - 506
EP - 516
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -